Moderna’s New European Team Readies For COVID-19 Vaccine D-Day
Gearing Up For A Huge Commercial And Manufacturing Challenge
Executive Summary
After a stunning first efficacy readout for its mRNA-based vaccine, the biotech company's leaders in Europe talk about their rapid commercial and manufacturing scale-up.
You may also be interested in...
AZ Will Sideline ‘Lucky Mistake’ To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
Moderna Aces COVID-19 Vaccine Results With 94.5% Efficacy
Moderna’s stunning interim results add to the world’s relief brought by Pfizer’s first read-out, and also provide the US biotech with the commercial platform it needed
Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports